Diabetic Kidney Disease
Patients suffering from Type 2 Diabetes have elevated blood sugar after meals. Like other endogenous pro-inflammatory substances, elevated blood sugar triggers a cascade of inflammatory processes which can damage different organs, including the kidneys.
Most people with Diabetic Kidney Disease do not have obvious symptoms. The patients will gradually have an increased and asymptomatic amount of protein in the urine. The disease is often diagnosed randomly during routine General Physician control.
Protein in urine is an indicator of inflammatory processes in various parts of the kidney. If the inflammation is left untreated, the kidney function deteriorates, and the patient will eventually require chronic dialysis or kidney transplant. Patients with Diabetic Kidney Disease have a higher morbidity and mortality.
The current standard treatment of Diabetic Kidney Disease is antidiabetics in addition to an antihypertensive drug. This therapeutic combination has demonstrated a significant decrease in urinary loss of protein and prolonged the time until dialysis. However, the combination of various antidiabetic and antihypertensive drugs are not a cure.
Consequently, when the diabetic inflammatory process develops further, urinary protein will increase again indicating disease progression.
Serodus’ pipeline of Diabetic Kidney Disease drugs are specifically targeting the, so far, therapeutically ignored anti-inflammatory processes – potentially extending the time to dialysis significantly.